RBM28

Across TCGA pan-cancer cohorts, RBM28 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated RBM28 data layer compared with 30 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RBM28 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RBM28 expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

PDAC, CCRCC, and GBM are the cancer types where RBM28 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.392	0.712	<.001	44	view →
CCRCC	DFS	Tertile	III,IV	0.301	0.700	.001	36	view →
GBM	OS	Median	All	0.706	0.342	.001	14	view →
UCEC	DFS	Median	II,III,IV	0.882	0.493	.025	8	view →
LUAD	DFS	Tertile	II,III,IV	0.919	0.749	.014	4	view →
LSCC	DFS	Quartile	II,III,IV	0.877	0.562	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

RBM28–PDAC (OS)

Open the PDAC breakdown →